Samsung Biologics (207940 KS): Synthetic Expert Call Transcript (29 Aug 2026)
Defensive Capital Structure Strategy: Samsung Biologics’ decision to fund the CHF 1.46 billion (KRW 2.71 trillion) PolyPeptide Group acquisition...
99 Views
Samsung Biologics - Impact of 3 Trillion Won in Rights Offering Capital Raise
On 28 August, Samsung Biologics (207940 KS) announced a rights offering capital raise worth nearly 3 trillion won, mainly to fund the acquisition...
124 Views
Korea: Short Selling Is Back in March; Trade Ideas
Short selling in Korea commences from Monday. There will be a lot of interest in shorting stocks/sectors depending on how they have performed since...
2k Views
Primer: Samsung Biologics (207940 KS) - Aug 2026
Samsung Biologics is the world's largest contract development and manufacturing organization (CDMO) by manufacturing capacity, positioning it as...
102 Views
Samsung Biologics (207940 KS): Robust 2Q Result; New Acquisition to Expand Modality into Peptides
​Samsung Biologics reports 30% revenue growth for 2Q26 and is on track to meet the upper end of FY guidance range. The company is acquiring...
121 Views